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Despite ongoing controversial expert discussions the European Medicines Agency (EMA) recently recommended to
suspend marketing authorisations for hydroxyethyl starch. This comment critically evaluates the line of arguments.
Basically, the only indication for a colloid is intravascular hypovolemia. Crystalloid use appears reasonable to
compensate ongoing extracellular losses beyond. In the hemodynamically instable patient this leads to the
distinction between an initial resuscitation phase where colloids might be indicated and a crystalloidal maintenance
phase thereafter. It is important to bear this in mind when reevaluating the studies the EMA referred to in the
context of its recent decision: i) VISEP compared ringer’s lactate to 10% HES 200/0.5 in septic patients and found an
increased incidence of renal failure in HES receivers. Unfortunately, study treatment was started only after initial
stabilization with HES, randomizing hemodynamically stable patients into a rational (crystalloids) and an irrational
(high dose starch until ICU discharge) maintenance treatment. ii) 6S compared ringer’s acetate to 6% HES 130/0.42
for fluid resuscitation in septic patients and found an increased need of renal replacement therapy and a higher
mortality in the HES group. However, patients of both groups were again randomized only after initial stabilization
with colloids, the actual comparison was, therefore, again rational vs. irrational. Beyond that, the documentation is
partly fragmentary, leaving many important questions around the fate of the patients unanswered. iii) CHEST
randomized ICU patients to receive saline or 6% HES 130/0.4 for fluid resuscitation. Actually, despite partly discussed
in a different way, this trial showed no relevant differences in outcome.
In all, two studies showed what happens to septic patients if starches are used in a way we do not observe in daily
practice. The third one actually proves their safety. The benefit of perioperative goal-directed preload optimization
using starches is unquestioned. Taking these informations into account, the recommendation of the EMA starches
to be generally dangerous remains mysterious and incomprehensible. An authority being able to dictate behavior
should stand clear from oppressively ending a worldwide expert discussion and step back into the role of the
observer until science achieves an agreement.
Keywords: Colloids, Crystalloids, Fluid therapy, Hydroxyethyl starch, SepsisAfter years of throwing crystalloids and colloids into one
pot, the last decade increasingly established a differenti-
ation between crystalloidal substitution of extracellular
losses and stabilization of cardiac preload beyond [1]. A
“goal-directed” approach to the latter with colloids has
been shown – at least for the perioperative setting - to
reduce morbidity [2] and is implemented in the British
Consensus Guidelines on Intravenous Fluid Therapy
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distribution, and reproduction in any mediumevidence suggested, however, that long-term use of
hydroxyethyl starches (HES) in high cumulative doses
could be a problem in septic patients. The discussion
even among experts is ongoing and remains controver-
sial [4,5].
Nevertheless, on June 14th 2013 the risk assessment
committee of the European Medicines Agency (EMA)
recommended to suspend marketing authorisations for
HES for all indications. In the following we will try to
clarify whether this was scientifically justified.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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volume effects
Normally, two-thirds of the total body water are intra-
cellularly, the remaining part is located extracellularly,
distributing to 80% interstitially and to 20% intravascu-
larly. These two extracellular sub-compartments are sep-
arated by the vascular barrier, sufficiently retaining
macromolecules, but being freely permeable to water
and electrolytes. This explains the observation that dur-
ing resuscitation of a bleeding patient with isotonic crys-
talloids the infused amount is distributed evenly over the
entire extracellular space, i.e., to 20% intravascular and
to 80% interstitial [6]. Iso-oncotically prepared colloids,
by contrast, remain nearly completely within a primarily
hypovolemic vascular system after i.v. infusion [7]. The
repeatedly expressed clinical suspicion that crystalloids
used for volume resuscitation might have a similar intra-
vascular persistence as colloids is wrong. The possible
advantage of colloids over crystalloids for stabilizing car-
diac preload is obvious: Crystalloids require the 4-5-fold
amount to sufficiently stabilize macrohemodynamics.
Most of this fluid would shift into tissue causing sub-
stantial interstitial edema [1], itself being associated with
increased mortality [8]. However, colloidal volume effects
of 80-100% only account for their use to correct intravas-
cular hypovolemia. Isooncotic fluids infused as a
hypervolemic bolus into the circulation of previously
normovolemic patients have been shown to have a reduced
volume effect of around 40%, thus, 60% being shifted to-
wards the interstitium. The reason is a hypervolemia-
related impairment of vascular barrier functioning [9].
The only rational indication for an i.v. colloid is acute
intravascular hypovolemia. Therefore, colloids are not
indicated in normovolemic patients. Beyond that, HES
is contraindicated in patients with acute renal failure.
The outcome-based view: evidence in fluid
therapy
In 2001 the group around Emanuel Rivers [10] taught us
one thing above all: failure to early hemodynamically
stabilize patients in acute shock is extremely difficult to
compensate for later. Quite obviously we must distin-
guish between an initial (6-hour) resuscitation phase of
hemodynamically instable patients and a maintenance
phase thereafter. During resuscitation volume therapy is
an important part of an outcome-relevant causal ther-
apy, deciding between life and death. Maintenance with
fluids is only one measure within a multifactorial sup-
portive concert and defining reliable outcome parame-
ters is as difficult as defining a reproducible standard.
It is important to keep this in mind when evaluating
the three trials the risk assessment committee of the EMA
was primarily referring to when recommending against
HES in general [11-13].VISEP, 6S and CHEST: what did they actually do?
The investigators of the VISEP trial [11] compared the use
of ringer’s lactate to that of 10% HES 200/0.5 for volume
replacement therapy in 537 septic patients. Receiving col-
loids following their protocol led to an increased incidence
of renal failure and “a trend towards higher 90-day mortal-
ity”, despite being non-significant. Unfortunately, study
treatment was started only up to 24 h after diagnosis of se-
vere sepsis. As the treating physicians were not passive in
between, at this time initial hemodynamic stabilisation
had already been completed in the vast majority of pa-
tients, the median values of mean arterial pressure (MAP),
central venous pressure (CVP), central-venous oxygen sat-
uration (ScvO2) and lactate at study onset having been
75 mmHg, 12 mmHg, 74% and 2.2 mmol/l, respectively.
This led to randomization into i) a “crystalloid” group in
which 58% had already successfully received up to 1 litre
of HES for initial resuscitation (remarkably, further 33% in
this group received colloids during the trial) and ii) a col-
loid group which received this outdated hyperoncotic so-
lution over a prolonged period of time outside a proper
indication and in daily and cumulative dosages beyond
any recommendation. Especially the latter aspect is im-
portant, as even in this study the subgroup of patients
who received this HES preparation in daily amounts within
the recommended range showed a lower mortality (!) than
the crystalloid group.
The 6S trial [12] compared the use of ringer’s acetate
to the application of 6% HES 130/0.42 for fluid resusci-
tation in 800 septic patients. Similar to VISEP, the au-
thors found an increased incidence of renal replacement
therapy (RRT) after the use of HES and, beyond that,
a significantly higher 90-day-mortality. However, also
similar to VISEP, patients were once again only random-
ized up to 24 h after diagnosis of severe sepsis or septic
shock into i) a "crystalloid" group in which over 60% had
already received up to 1,000 ml of colloid for initial
resuscitation and ii) a colloid group in which the major-
ity of patients was already hemodynamically stabilized,
the baseline median values of CVP, ScvO2 and lactate
having been 10 mmHg, 75% and 2.0 mmol/l, respect-
ively. According to the recommendations of the Surviv-
ing Sepsis Campaign these values are even better than
the targets of fluid resuscitation [14] - so most certainly
not a trigger. Therefore, in this study the colloid re-
ceivers were, once again, tested for a non-indicated drug,
in comparison to the rational and well established ap-
proach with crystalloidal maintenance in stable patients.
Additionally, 36% of the randomized patients had renal
failure already at study onset, a clear contraindication of
HES. Moreover, 216 patients in both groups (27%)
discontinued trial fluid during the study and 32% of the
“crystalloid” group received colloids during (!) the trial.
Nevertheless, all were included into the 90-day follow-
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several other important values, the documentation of
which would have been part of the protocol, were not
indicated (e.g. hematocrit, (mean) arterial pressure or
data on mechanical ventilation). The objective criteria
for assessing renal failure (the RIFLE-score) are reported
in the supplement and show no significant differences.
This is not mentioned nor discussed manuscript.
Hemodynamical parameters are reported only for the
first 24 hours. Although the trial theoretically went on
for 90 days, the length of hospital and ICU stay is not
reported and the use of study and non-study fluids is
only stated for the first 3 days. It has to be concluded
that we do not know enough about what actually hap-
pened to these patients. Obviously, in this trial the ma-
jority of the “crystalloid” group received colloids during
initial stabilization, i.e., with a good indication and 1/3
even during the trial. After stabilization, they were ran-
domized into a rational (crystalloids) or an irrational
(colloid) maintenance protocol, receiving HES in high
amounts and over a prolonged period of time. Consider-
ing the lack of a proper indication in the majority and
an absolute contraindication in a large part of the pa-
tients, negative effects are not surprising. It is simply not
possible to conclude pure crystalloidal treatment to be
superior to the use of colloids from a study where prac-
tically every patient also in the crystalloid group received
some kind of colloid.
The CHEST trial [13] randomized 7,000 patients, at
mean 11 hours after ICU admission, to receive saline or
6% HES 130/0.4 for fluid resuscitation. The authors
reported a main analysis which found no differences in
mortality or renal function according to the RIFLE cri-
teria, but an increased incidence of RRT after HES infu-
sion in the non-adjusted analyses. They tried to explain
this by post-hoc tests, allegedly showing higher relative
risks for the HES receivers to develop renal insufficiency
states “RIFLE-R” (risk of renal failure) and “RIFLE-I”
(kidney injury). This is quite simply not true, as can be
easily taken from Table 1, nor is it even possible. In gen-
eral, post-hoc tests evaluate where effects from a main
analysis might come from - as a matter of fact theyTable 1 A modified excerpt of the original ‘Figure S3’ in the s
RIFLE category and component HES n/N (%) Saline n/N (%
RIFLE-R (risk) 1788/3309 (54.0) 1912/3335 (5
Creatinine increase (x1,5) from baseline 462/3149 (14.7) 415/3171 (13
Urine output <0.5 ml/kg/h x 6 h 1701/3230 (52.7) 1846/3266 (5
RIFLE-I (injury) 1130/3265 (34.6) 1253/3300 (3
Creatinine increase (x2) from baseline 245/3149 (7.8) 191/3171 (6.0
Urine output <0.5 ml/kg/h x 12 h 1077/2977 (36.2) 1200/3024 (3
The results clearly contradict the statement in the original manuscript that in subgr
for the risk of kidney dysfunction (RIFLE-R) or kidney injury (RIFLE-I) in the HES groucannot contradict this main analysis. Why patients with
the better renal function (according to the objective RIFLE
criteria) had a slightly higher rate of RRT (subjective as-
pect) remains unclear (7.0% vs. 5.8%, p = 0.04). The most
likely explanation is that there were no standardized trig-
gers for this supportive measure. Therefore, first of all, not
more patients required but received RRT. Interestingly, in
the adjusted analysis (a standard procedure to eliminate
influence by, e.g., age, gender or severity of illness) there
was no difference in the incidence of RRT in this trial.
That actually should have led to the conclusion that, due
to an improved kidney function and no differences in
RRT, CHEST shows an advantage for HES. Moreover, the
protocol was violated 953-times in 634 (9.5%) patients by
infusing the wrong study fluid. All these patients remained
in the trial. This means that there were more patients
receiving the wrong fluid than RRT, making a result
being influenced by chance at least possible. Mean
hemodynamic values at baseline in the HES group were
MAP 74 mmHg, CVP 9.5 mmHg and lactate 2.1 mmol/l,
all exceeding the recommended targets of the Surviving
Sepsis Campaign. This reveals hemodynamic stability and
no need for colloidal fluid resuscitation. Also in this trial
36% of the patients had acute renal failure at randomisa-
tion (an already mentioned contraindication for HES) and
508 patients in the saline group had received HES prior to
randomisation. Use of other colloids was not reported.
Notably, 30% of the patients were septic and in this sub-
group no differences in mortality, renal failure or renal re-
placement therapy were observed.
Summarizing the three trials, one showed no relevant
differences [13] while two suffered from protocols not
reflecting clinical reality, ignored contraindications and
maximum recommended daily doses, discarded indica-
tions for starches, over-interpreted the results and/or
hide important facts in attachments and appendices
[11,12]. Importantly, not one of them evaluated the ini-
tial 6-hour phase shown to be crucial for patient out-
come [10]. However, in all trials colloids were given to
the majority of patients in this crucial phase, also in the
crystalloid groups. In the starch groups, the wrong fluid
(the indication suggested crystalloids) in the wrongupplementary appendix of the CHEST trial [13]
) Relative risk 95% confidence interval p Result
7.3) 0.94 (0.90-0.98) 0.007 HES better
.1) 1.12 (0.99-1.27) 0.07 n.s.
6.5) 0.93 (0.89-0.97) 0.002 HES better
8.0) 0.91 (0.85-0.97) 0.005 HES better
) 1.29 (1.08-1.55) 0.006 Saline better
9.7) 0.91 (0.85-0.97) 0.005 HES better
oup analyses “post-hoc tests show a higher relative risk of meeting the criteria
p than in the saline group”.
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time (after stabilization) in the wrong patients (many
had acute renal failure and most were hemodynamically
stabilized) was infused. Therefore, side-effects and com-
plications are no surprise. These trials show that
starches should not be infused during sepsis after the
initial stabilization phase. With the above-mentioned
shortcomings, however, they do not provide evidence for
safety issues of starches outside this very special (contra-)
indication. Most certainly they do not challenge the know-
ledge that isooncotic colloids are vital drugs in the peri-
operative setting. Recent meta-analyses in this collective
have shown that non-septic patients receiving 6% HES
130 with a proper indication could have a superior risk/
benefit ratio and improved outcome compared to crystal-
loids [2,15].
Conclusion: what will the future bring?
In contrast to oral discussions and opinion papers, the
EMA has the power to dictate behaviour to clinicians.
This is associated with a great responsibility. Therefore,
in our understanding such an authority should stand
clear from controversial discussions among experts,
avoiding extrapolation of data from one to another clin-
ical situation and keeping to facts. As the official recom-
mendation in it’s current form is not based on reliable
data it arbitrarily takes an important drug out of the
hands of physicians who do exactly what they should do:
Pay attention to physiological principles and stick to the
objective available data, to the benefit of their patients.
We are quite sure that this was not intended. We hope
that the European Medicines Agency will use the
current revision procedure for re-thinking and getting
back from a politically driven to a scientific issue, limit-
ing the use of starches to an indication-centred one.
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